February 19, 2026 update: A not yet recruiting clinical trial compares standard ACL reconstruction with a TARS augmented approach to evaluate safety and performance for a regulated medical device. This article summarizes what the trial seeks to measure and how regulators may view the study within the MDR framework.
What changed in ACL reconstruction practice?
ACL reconstruction has long relied on standard grafting techniques. The trial from Samsun University introduces a TARS augmented approach as an alternative in the setting of ACL repair. The comparison aims to inform researchers, clinicians, and regulators about relative safety and performance of the two strategies in a controlled clinical environment. The change lies in the integration of a device assisted augmentation to the procedure, which may alter risk profiles and regulatory considerations. The path to adoption depends on evidence generated by this study and alignment with MDR requirements for medical devices used in surgery.
How is the trial designed?
The ClinicalTrials.gov record NCT07418476 lists the condition and intervention as ACL related and notes Samsun University as sponsor. The status is not yet recruiting and the study is described as a head to head comparison of standard ACL reconstruction and TARS augmented reconstruction. The design details available publicly primarily indicate a comparative framework to evaluate safety and performance rather than efficacy claims. Readers should monitor official updates for amendments to enrollment, endpoints, and analytic plans. Regulatory teams should anticipate documentation needs around device labeling, risk assessment, and conformity with MDR Annex XIV requirements.
What regulatory considerations apply to a TARS augmented approach?
Under MDR, the intended purpose, performance claims, and safety profile of any device used in the TARS augmented reconstruction would be subject to regulatory evaluation. The sponsor should clearly delineate the device’s intended use in the trial protocol and classify the product appropriately. Statements from the sponsor would be treated as manufacturer claims and require substantiation by clinical data. The trial status not yet recruiting means pre enrollment steps including ethics approval, device assessment, and risk management are in progress or planned. Clinicians and regulatory professionals should track the trial for changes that affect device labeling, postmarket surveillance, and reporting obligations.
What is known about safety and evidence in this area?
Publicly available information for this trial is limited to the record on ClinicalTrials.gov and the sponsor attribution. As with any device guided augmentation used in ACL surgery, safety considerations include graft stability, device related complications, and surgical outcomes. Because the comparison involves a device augmented reconstruction, readers should expect a data package that addresses risk controls, sterilization standards, and operator training as part of the evidence package. Regulators will look for robust safety data and transparent reporting plans before approval or clearance for broader use. The absence of recruitment activity at this stage underscores the need for careful evaluation of risk, benefit, and patient selection criteria once enrollment commences.
Implications for practice and regulation
If the trial demonstrates a favorable balance of safety and performance, hospitals and surgeons may consider including TARS augmented reconstruction as a potential option in the regulated surgical toolkit. Regulatory implications would center on continued surveillance, device performance reporting, and alignment with MDR requirements. Clinicians should prepare for training and credentialing implications if the device adoption proceeds, and manufacturers should be ready to provide evidence to support labeling and risk management plans.
FAQ
- Q1 Where can I find official trial details? A1 The trial is registered on ClinicalTrials.gov under NCT07418476 and lists Samsun University as sponsor.
- Q2 What is being compared in this study? A2 The study compares standard ACL reconstruction with a TARS augmented reconstruction in patients with ACL related conditions.
- Q3 What is the status of enrollment? A3 The record indicates not yet recruiting and status updates are expected from the sponsor.
- Q4 What should I watch for in regulatory terms? A4 Look for defined intended use, device classification, risk management and reporting obligations consistent with MDR.
Conclusion
In summary, the Samsun University trial has the potential to inform both clinical practice and regulatory oversight for a graft augmentation approach in ACL surgery. Stakeholders should follow interim updates on enrollment, endpoints and safety data. The ultimate goal is to establish a clear, substantiated regulatory pathway that defines the device’s intended use and safety characteristics while ensuring patient protection.
Disclaimer
This article is intended for clinical, quality and regulatory professionals. It does not constitute legal advice or regulatory guidance. Consult official MDR texts and the ClinicalTrials.gov record for definitive information.
https://clinicaltrials.gov/study/NCT07418476?term=medical+device